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Background: Novel-targeted therapies are in rapid development for the treatment of acute lymphoblastic leukemia
(ALL) to overcome resistance and decrease toxicity. Survivin, a member of the inhibitor of apoptosis gene family
and chromosome passenger complex, is critical in a variety of human cancers, including ALL. A well-established
suppressor of survivin has been the small molecule, YM155. Reports are identifying other mechanisms of action for
YM155. Therefore, we sought to investigate the mode of action and role of YM155 for therapeutic use in the
context of ALL.
Methods: Primary ALL samples and ALL cell lines were interrogated with YM155 to identify drug sensitivity. Ph+ALL
harboring the BCR-ABL1 oncogene were tested for any interaction with YM155 and the multi-kinase inhibitor
dasatinib. Representative ALL cell lines were tested to identify the response to YM155 using standard biochemical
assays as well as RNA expression and phosphorylation arrays.
Results: ALL samples exhibited significant sensitivity to YM155, and an additive response was observed with
dasatinib in the setting of Ph+ALL. ALL cells were more sensitive to YM155 during S phase during DNA replication.
YM155 activates the DNA damage pathway leading to phosphorylation of Chk2 and H2AX. Interestingly, screening
of primary patient samples identified unique and exquisite YM155 sensitivity in some but not all ALL specimens.
Conclusion: These results are the first to have screened a large number of primary patient leukemic samples to
identify individual variations of response to YM155. Our studies further support that YM155 in ALL induces DNA
damage leading to S phase arrest. Finally, only subsets of ALL have exquisite sensitivity to YM155 presumably
through both suppression of survivin expression and activation of the DNA damage pathway underscoring its
potential for therapeutic development.
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B-cell precursor acute lymphoblastic leukemia (ALL),
the most common pediatric malignancy, affects all age
groups and carries a high treatment burden. Tremendous
strides have been successful in improving the treatment
and cure of this disease (review [1]). Unfortunately, stand-
ard cytotoxic treatment continues to expose the patient to* Correspondence: changb@ohsu.edu
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unless otherwise stated.long-term morbidity and mortality. Therefore, novel-
targeted therapies will be essential to decrease therapeutic
burden of ALL. To that end, multiple targets have recently
been identified and novel therapies are now being tested
both in preclinical and clinical studies [2].
Survivin (BIRC5) is a small protein that belongs to the
inhibitor of apoptosis (IAP) family and chromosome pas-
senger complex (review [3,4]). Survivin is an attractive tar-
get for therapy because it is expressed predominantly
during development and in the setting of malignancies
with little to no expression in terminally differentiated tis-
sue [5-7]. Further, survivin overexpression has correlatedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,











































Figure 1 Response to YM155 of primary ALL and AML patient
samples. Primary patient and xenografted samples were collected as
previously described [14]. (A) Samples were then incubated with
increasing concentrations of YM155 (0 nM to 1 μM) and IC50 were
calculated using a second-order polynomial. (Filled triangle) ALL
samples without a recurring cytogenetic abnormality; (filled
diamond) ALL with t(9;22); (filled circle) ALL with 11q23 rearrangement
or MLL rearrangement; (filled square) ALL with <44 chromosomes or
hypodiploid; (open triangle) ALL with t(1;19); (open square) ALL with
t(12;21); (open circle) ALL with hyperdiploid; (grey square) total ALL;
(grey triangle) total AML samples. Statistical significance of p < 0.05 by
Student’s t-test between total ALL and AML samples. Samples with
IC50s within the shaded area are within levels achievable in phase 1
pharmacokinetics [30]. Horizontal line denotes median IC50 of all tested
samples. (B) Dose–response curves of two AML-resistant samples (red
filled circle, red filled square), one ALL resistant sample (red filled
triangle), one ALL intermediate sample (purple open square), and two
sensitive ALL samples (black filled diamond, black filled circle). Numbers in
parentheses denote patient number (Additional file 2: Table S1 and S2).
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[8] while suppressing expression in ALL decreases che-
moresistance [9,10]. Although several mechanisms of
survivin inhibition have been studied, early trials have
shown minimal success in targeting this protein for
clinical benefit [11].
YM155 (sepantronium bromide) is a small molecule
originally discovered as a suppressant of survivin expres-
sion [12]. YM155 has shown potent antiproliferative ef-
fects on a variety of human cancer cell lines [13].
Although no human trials have been designed to test
this drug in ALL, it has theoretical potential for clinical
benefit. We recently verified the utility of YM155 in de-
creasing survivin expression in pediatric ALL [14]. These
studies also found that survivin suppression by YM155
was not the sole effect that caused cell death. Specific-
ally, in primary ALL patient samples, sensitivity did not
correlate with survivin expression. In fact, other investi-
gators have shown that YM155 has the potential to
cause cell death by mechanisms other than survivin re-
pression in different disease models [15-18]. One intri-
guing concept is that YM155 has the potential to cause
DNA damage thereby increasing cell death [15,18]. In
the following studies, we used a rapid functional assay
on fresh primary leukemic samples to identify sensitivity
to YM155 and further validate the mechanism of action
of YM155 in the setting of ALL.
Results
Primary patient ALL samples are significantly more
sensitive to YM155 as compared to primary patient AML
samples
We have recently developed a technique to assess sensitiv-
ity to small molecule inhibitors from primary patient
leukemic samples obtained at diagnosis [19]. Using this
platform, we interrogated over 40 ALL and 65 AML sam-
ples for sensitivity to YM155 (Figure 1A). These primary
patient samples exhibited a diverse range of sensitivity to
the drug. For each subgroup, the number of samples within
the subgroup, the median IC50, mean IC50, standard devi-
ation, and standard error are shown in Table 1.The ALL
samples appeared to have a bimodal distribution of IC50s.
One group showed significant sensitivity while another
group showed a relative resistance to the drug. Due to this
distribution, the median IC50 for the ALL samples was cal-
culated to 45 nM (Table 1). In contrast, the majority of
AML samples showed minimal sensitivity to YM55 with a
calculated median IC50 of 900 nM. Sensitive samples
showed robust inhibition of viability whereas resistant
samples showed no toxicity from YM155 up to 1 μM
(Figure 1B). One ALL subgroup, samples with t(9;22)/
BCR-ABL1 (Ph+ALL), appeared quite sensitive to YM155,
though the sample size of each genetic subgroup was too
small to achieve statistical significance (Figure 1A).YM155 shows synergy with dasatinib in Ph+ALL
Our previous report supported the concept of inhibiting
survivin expression in Ph+ALL as a therapeutic option
Table 1 Number of samples within each subgroup, the median IC50, mean IC50, standard deviation, and standard error
Disease B-ALL t(9;22) 11q23 hypoD t(1;19) t(12;21) hyperD ALL total AML
Number 7 10 7 7 1 3 7 42 69
Median 16.31 12.34 684.9 46.45 576.4 43.41 310 44.54 918.3
Mean 389.4 183.1 544.1 292.2 576.4 179 343.6 331.6 712.4
Std. deviation 484.4 363.3 483.4 420.3 0 258.3 381.9 406.3 327.9
Std. error 183.1 114.9 182.7 158.9 0 149.1 144.4 62.69 39.48
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(e.g., BCR-ABL) for which targeted agents are available
(e.g., imatinib, dasatinib), we next wanted to test
whether YM155 would have benefit in combination with
dasatinib. Indeed, there appeared to be additive/synergy
with this combination (Figure 2A). Further, YM155 sen-
sitivity appeared to be maintained in primary Ph+ALL
samples, xenografted samples, and in samples with
dasatinib-resistant mutations (Figure 2B). To further ad-
dress the combination of dasatinib and YM155, we per-
formed knockdown experiments using siRNA to ABL1.
Reduced expression of BCR-ABL1 did not enhance or
reduce sensitivity to YM155 suggesting an additive effect
of YM155 and dasatinib (Figure 2C).
We next wanted to validate our previous data that
showed that inhibition of survivin expression would lead
to phosphorylation of p53 [14]. To determine whether
sensitivity to YM155 is universally related to p53 activa-
tion, we developed a phosphoflow assay using ser15
phospho-p53 (Figure 2D). Both REH and RCH cell lines
showed robust enhancement of phospho-p53 signal. In
contrast, Ph+ALL cell lines and xenograft samples SFO2
and BLQ5 showed minimal increase of p53 phosphoryl-
ation using a dose closer to an IC90 of 100nM, despite
both lines showing sensitivity to YM155. These results
suggest alternative mechanisms for YM155 sensitivity
beyond p53 activation.
YM155 causes an S phase arrest in ALL cells
The unexpected results of our p53 phospho-flow assay
led to the possibility that YM155 may not be activating
p53 through survivin suppression alone. To begin to test
this hypothesis, we chose to interrogate what effects
YM155 had on the cell cycle. Survivin expression has
been closely linked with the cell cycle with minimal ex-
pression until G2/M [20], suggesting that a reduction in
survivin levels would result in a G2/M arrest. Yet, previ-
ous studies suggest that YM155 has effects on survivin
expression independent of the cell cycle [21]. In contrast
to prior published results, we did find a subtle increase
in the number of cells in S phase when treated with 100
nM YM155 for 24 h in REH, RCH, and SUPB15 cells
(Figure 3A). Further, we see a slight increase in the
subG1 population consistent with an increase in apop-
totic cells (Table 2).These findings would suggest that YM155 can cause
an S phase arrest supporting effects during DNA replica-
tion. To determine the stage of the cell cycle where
YM155 has the most significant effects, we stained a live
asynchronous population of REH cells with either
Hoescht or Vibrant DyeCycle Violet and sorted for cells
in G1, S, or G2/M phase. The sorted cells were plated in
increasing concentrations of YM155 (0 to 100 nM) for
24 h and tested for viability with MTS and apoptosis
with annexin V staining. The cells in S phase appeared
to be significantly more sensitive to YM155 at these doses
by both decrease in cell viability by MTS and increase in
early apoptosis by annexin V staining (Figure 3B). Taken
together, these data suggest that YM155 has significant ef-
fects on the cells in S phase, a time of minimal expres-
sion of survivin [14]. Therefore, YM155 may have other
effects independent of its ability to suppress expression
of survivin in ALL.
YM155 has effects on gene expression and phosphorylation
Studies have argued that other genes such as MCL1 can
be downregulated by YM155 (Additional file 1: Figure
S1 and [22]). In order to determine what other genes
may play a role in YM155 sensitivity, we used the p53
RT2 Array (84 genes). This assay allowed us to evaluate
gene expression changes of 84 genes after a 24-h treat-
ment of asynchronous cells with 100 nM YM155, in-
cluding survivin and Mcl1. We identified a variety of
genes that exhibited at least a twofold change in mRNA
expression level after exposure to YM155 (Figure 4A).
Two p53 wild-type cell lines REH and SUPB15 showed a
twofold decrease in survivin (BIRC5) expression. Both
cell lines show similar decreases in other genes such as
BRCA1 and CCNE2. The p53 mutant cell line K562,
which is quite sensitive to YM155 [13], showed virtually
no change in survivin expression. In all three cell lines,
genes known to be involved in DNA damage response,
such as GADD45A and JUN [23], were upregulated sug-
gesting that YM155 may induce more global effects on
the cells through DNA damage.
Since our previous studies showed that p53 phosphor-
ylation increases with YM155 treatment [14], yet p53
mutant cells are still sensitive to YM155, we chose to iden-
tify other signaling pathways that are affected by YM155
treatment. ALL cell lines were treated with 100 nM
Figure 2 (See legend on next page.)
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Figure 2 Ph+ALL samples are sensitive to YM155. (A) The Ph+ALL cell line SUPB15 was tested for sensitivity to dasatinib (top left) and YM155
(Top right) with increasing concentrations of drug (0 nM to 10 μM). The IC50 for each drug was approximately 10 nM. Combination of YM155
and dasatinib on SUPB5 cells showed a decrease in IC50 suggestive of synergy/additive by isobologram analysis [34]. Dose–response of SUPB15
cells with YM155 was carried out with increasing concentrations of dasatinib (bottom left). IC50 of individual drug alone was used as the
reference value of 1 and subsequent IC50 of combination of drugs were compared (bottom right). Points on the red dotted line would be
additive, while points left of the line would be synergistic and points on the right would be antagonistic. (B) Sensitivity to YM155 and dasatinib
was further tested on primary Ph+ALL patient samples (10–668) and xenograft samples (10–668 xenograft, ICN1, SFO2, TXL3, LAX2, BLQ5,
x10-378). Red samples signify dasatinib-resistant T315I mutants. (C) Knockdown of BCR-ABL1 expression. SUPB15 were treated with either
non-specific (NS) or ABL1 siRNA. The cells were then incubated in increasing concentrations of YM155 (0 to 1 μM) for 4 days and then assayed
for viability with MTS. Top panel describes the viability of the cells normalized to NS without YM155 exposure. Bottom panel describes the viability
normalized to with NS or ABL1 without YM155 exposure. An aliquot of electroporated cells were used for immunoblot analysis of BCR-ABL1
knockdown 3 days after electroporation. (D) P53 Ser-15 phospho-flow after treatment with YM155. Each cell line (REH, RCH, HAL01, and SUPB15)
and xenograft samples (SFO2, BLQ5) were treated with 100 nM YM155 for 24 h. (Red peak) Control signal for ser15-phospho-p53. (Blue peak)
YM155 treatment. REH and RCH cells showed a distinctive increase in phosphorylation of p53. In contrast, the Ph+ALL cells showed minimal
increase in p53 phosphorylation.
Figure 3 YM155 causes an S phase arrest. (A) Cell cycle arrest with YM155 treatment. An asynchronous population of cells (REH, RCH, and
SUPB15) were treated with 100 nM YM155 for 24 h and assayed for DNA content by propidium iodide. (Grey line filled) Control asynchronous
population. (Blue line) YM155 treatment. Bars indicate the cell cycle (subG1, G1, S, G2/M). All three cell lines show an increase in S phase and a
slight increase in the sub G1 phase within 24 h of treatment. (B) YM155 treatment has a greater effect when exposed to cells that are in S phase
of the cell cycle. An asynchronous REH population was sorted by DNA content for G1, S, and G2/M and treated with increasing concentration of
YM155 (0 to 100 nM) for 24 h, then assessed for viability using an MTS colorimetric assay (middle panel) or for Annexin V staining (right panel).
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Table 2 Percent of subpopulations within the cell cycle
with YM155 treatment
subG1 (%) G1 (%) S (%) G2/M (%)
REH
Control 1 61 16 21
YM155 3 61 20 13
RCH
Control 4 62 19 15
YM155 6 55 24 15
SUPB15
Control 2 63 21 13
YM155 5 51 31 10
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in phosphorylation using a phospho-proteome array
(Figure 4B). As seen in our phospho-flow assay, REH
cell showed a significant impact of YM155 on p53 phos-
phorylation while SUPB15 cells showed minimal increase
in p53. Instead, both cell lines showed a dramatic increase
in Chk2 at (Thr68). HAL01 cells, known to be resistant
to YM155, showed minimal change in phosphorylation.
These results would identify Chk2 phosphorylation as a
downstream effect of YM155 treatment.
YM155 increases phospho-Chk2 and direct DNA damage
These studies point to the possibility that YM155 in-
duces a DNA damage response during S phase. Previous
reports have also implied that the structure of YM155
has the potential to cause DNA damage similar to chro-
momycin A3, bisantrene HCl, and actinomycin D
[15,18]. To validate our results from the phospho-
proteome array, ALL cells were treated with YM155 with
10 and 100 nM for 24 h and immunoblotted for
phospho-T68 Chk2, total Chk2, and survivin (Figure 5A).
As another marker for the cells in G2/M, the extracts
were immunoblotted for Aurora B kinase. In addition to
YM155, the cells were also treated with a known DNA
damaging agent doxorubicin and with dasatinib. REH,
RCH, and SUPB15 cells all show a dose-dependent in-
crease in phospho-T68 Chk2 in support of the proteome
results. Doxorubicin treatment shows a similar increase
in Chk2 phosphorylation. Although there is a dose-
dependent decrease in survivin, there is also a decrease
in Aurora B kinase expression suggesting the decrease in
survivin may be due in part to an S phase arrest. In con-
trast, dasatinib does not significantly impact either phos-
phorylation or expression.
Upon sensing DNA damage, the phosphatidylinositol
3′-kinase-related kinases (PIKKs) become activated and
phosphorylate three important substrates, p53 (at serine
15), Chk2 (at threonine 68), and histone H2AX (at
serine 139) [24]. We have already identified that p53 andChk2 are phosphorylated when exposed to YM155. To
test whether H2AX is phosphorylated at serine 139
(γH2AX), we treated YM155-sensitive cell lines with 10
and 100 nM YM155 for 24 h, partially fixed and assayed
for DNA content and γH2AX (Figure 5B as described in
[25]). Each cell line showed a dose-dependent increase
in γH2AX staining in G1 and S phase. To further test
for DNA damage, we performed comet assays after
treatment with 100 nM YM155 for 24 h (Figure 5C).
REH cells showed significant damage after treatment.
Further, RCH, SUPB15 cells, and the p53 mutant K562
cells also showed significant DNA damage from YM155
with minimal change after 24-h treatment with 100 nM
dasatinib. These results confirm that YM155 activates
the DNA damage pathway independent of p53 activity.Discussion
Molecular targeting of survivin has been an intriguing
concept for therapy. Unfortunately, it has been a difficult
protein to target as this protein has no known catalytic
activity (review [3]). One of the compounds with the
most preclinical and clinical data is YM155. YM155 was
originally identified as a specific inhibitor of survivin ex-
pression from a high throughput screen using a survivin
promoter luciferase assay [12]. Since its first description,
there have been multiple studies that have validated this
compound as being selective for survivin expression
[13,21,26]. There is now emerging data that YM155 may
have more off-target effects causing cell death, including
inhibition of Mcl1 expression and direct DNA damage
[15,17,22]. Our studies further validate that YM155 has
the potential to activate the DNA damage response
through an S phase arrest that can increase p53, Chk2,
and H2AX phosphorylation eventually leading to apop-
tosis. These results, consistent with prior studies show-
ing direct DNA damage by intercalation [18], are the
first to be described in acute lymphoblastic leukemia
cells. Further, our results are the first to have screened a
variety of primary hematologic malignancies showing a
significant amount of heterogeneity. As DNA damaging
agents are a mainstay of therapy for ALL, it is critical
that these studies highlight the exquisite sensitivity to
YM155 and the mechanisms of action in ALL.
Prior studies have suggested other DNA damaging
agents such as doxorubicin increase survivin expression
in p53 intact leukemic cells [27]. In those studies, an in-
triguing concept of combination therapy with doxorubi-
cin and survivin suppression was proposed. Further
studies identified that YM155 can further inhibit
radiation-induced DNA repair [28]. Although the authors
ascribed this phenomenon to inhibition of survivin expres-
sion, another possibility would be that YM155 was further
inducing DNA damage.
Figure 4 (See legend on next page.)
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Figure 4 YM155 activates DNA damage response. (A) YM155 has multiple effects on RNA expression. REH (wild-type p53), SUPB15 (wild-type
p53), and K562 (mutant p53) cells were treated with 100 nM YM155 or vehicle for 24 h and mRNA expression levels of 84 genes were evaluated
using the P53 RT2 Array. Treatment with YM155 caused about a twofold decrease in survivin mRNA (BIRC5) in the p53 intact cells, but had minimal
impact on survivin expression in K562 cells despite potent effects of YM155 on K562 cell growth/viability (IC50 of <10nM [13]). Meanwhile, other genes
such as JUN and GADD45A involved in DNA damage response exhibit increased expression after YM155 treatment in all three cell lines. (B) YM155
treatment greatly enhances phosphorylation of Chk2. REH, SUPB15, and HAL01 cells were treated with either vehicle or 100 nM YM155 for 24 h, and
protein phosphorylation patterns were assessed using Proteome Profiler Arrays. Values were quantified and normalized to untreated control for each
site. REH cells show p53 and Chk2 with the largest change in phosphorylation. SUPB15 shows only Chk2 with the largest change in phosphorylation.
HAL01 cells, known to be resistant to YM155 showed minimal change in phosphorylation.
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stay in the treatment of leukemia. It is a highly effective
drug but carries with it both significant short-term and
long-term side effects including myelosuppression and
cardiac toxicity. Our studies would suggest at least two
possibilities. First, in future clinical trials testing YM155,
concurrent use of DNA damaging agents such as doxo-
rubicin may be discouraged for possible compounding of
toxicity. Second, if YM155 is shown to have some effi-
cacy in pre-selected patients, future studies could be de-
signed to substitute YM155 for anthracyclines which
may decrease long-term side effects.
One of the most intriguing results of these studies is
the heterogeneity of sensitivity of primary patient sam-
ples. Our study is the first to have screened a multitude
of primary patient samples. Overall, a subset of ALL
samples appears to be quite sensitive compared to AML
samples. Further, all tested subtypes such as hypodiploid,
MLL-rearranged, and Ph+ALL have samples that are
quite sensitive while others remained resistant. Unfortu-
nately, our sample size was not powered to find a correl-
ation between sensitivity and current prognostic features
such as cytogenetic subtypes. Instead, our studies high-
light the power of a functional assay to predict individual
patients that could respond to drug. This heterogeneity
of response may explain in part why current clinical tri-
als testing YM155 have shown minimal success. Our
functional results predict that individuals need to be pre-
selected for YM155 sensitivity. Only then could a trial
show benefit from testing this drug.
Our previous results from primary patient samples did
not find a correlation with survivin expression and
YM155 sensitivity [14]. One intriguing possibility for this
heterogeneity lies in the expression of the solute carrier
SLC35F2 [18]. Their studies suggest that the DNA dam-
age sensitivity by YM155 correlates with expression of
SLC35F2. Although these studies did not interrogate
leukemic samples, their findings may address in part the
heterogeneity seen in leukemia. For example, ours stud-
ies showed that the HAL01 cell line appeared the least
sensitive to YM155. This cell line and primary ALL with
the t(17;19) have previously been shown to have higher
expression of the efflux protein ABCB1 [29], suggestingdrug efflux as an important mechanism of resistance.
Therefore, future studies will be needed to identify a
specific marker to predict in vitro response to YM155 in
ALL samples.
In the original article by Nakahara et al., they de-
scribed a broad distribution of sensitivities to YM155 in
malignant cell lines tested including many solid tumors
[13]. In their orthotopic animal studies, YM155 treat-
ment suppressed tumor growth on samples with GI50 of
5–20 nM. In these animal studies, YM155 was well tol-
erated with minimal side effects at therapeutic doses.
Further, in previous phase 1 clinical trials with YM155,
plasma concentrations of approximately 25 nM were
achieved that were also well tolerated with minimal side
effects [30]. These inhibitory concentrations are well
within the IC50s of our sensitive primary patient samples
predicting the possibility of in vivo response to YM155.
Current clinical trials testing the efficacy of YM155 as
a single agent and in combination with either immuno-
therapy or cytotoxic chemotherapy have verified that the
drug is quite tolerable in these scenarios (review [31]).
Unfortunately, there have been very minimal responses.
Our data supports the concept of YM155 as an excellent
candidate drug to add to therapeutic regimens only in a
subgroup of patients that have a pre-selected possibility
of responding. This includes patients with Ph+ALL who
may benefit from combination therapy. Our concept
would be as a combination for patients with recurrent
ALL that have been shown to be sensitive in vitro as se-
lection to enroll on the therapeutic trial. The caution is
that because of the heterogeneity of the drug response,
future trials testing YM155 in patients need to pre-select
the sensitive population to validate its efficacy.
Conclusions
Our studies are the first to interrogate a significant num-
ber of primary leukemic samples for functional sensitiv-
ity to YM155. These results show the potential benefit
of rapid functional preselection of patients that could
potentially respond to drug. Further, we identify that
ALL has a unique subset that is exquisitely sensitive to
this drug. The ALL cell lines further identify that
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Figure 5 YM155 activates DNA damage response with S phase arrest. (A) Immunoblot verifies the increase in threonine 68 phosphorylation of
Chk2. REH, RCH, and SUPB15 cells were treated with increasing concentrations of YM155 (0, 10, 100 nM), doxorubicin (0.1 μg/ml) or dasatinib (100
nM) for 24 h. Whole cell lysates were subjected to immunoblot using antibodies specific for phospho-T68 Chk2, total Chk2, survivin, and Aurora B
kinase. (B) Treatment with YM155 causes an increase in γH2AX. REH, RCH, and SUPB15 cells were treated with vehicle or YM155 (10 and 100nM)
for 24 h and then stained with γH2AX-FITC and Vibrant DyeCycle Violet Stain. The cells were quantified using FACS/AriaIII for DNA content and
FITC. Treatment with YM155 in each cell line showed a dose-dependent increase in γH2AX-FITC, mostly in G1 and S. (C) Comet assays of leukemia
cell lines identify DNA damage. REH, RCH, SUPB15, and K562 cells were treated with 100 nM YM155 and 100 nM Dasatinib (excluding REH) for
24 h. Top panel is the box-whisker plot of the percent of DNA in the comet tail after treatment. Bottom panels are photographic representations
of the comet assays for each cell line.
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DNA damaging agents. Future studies will be needed to
identify the mechanism of selective sensitivity of YM155
in ALL to select patients that would have the capacity of
responding to this drug for therapeutic effect.Methods
Chemicals and reagents
Fetal bovine serum was obtained from Hyclone (Thermo
Scientific, Rockford, IL). All other tissue culture reagents
were obtained from Invitrogen (Grand Island, NY).
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ous One solution cell proliferation assay (MTS) from
Promega (Madison, WI). YM155 was purchased from
Selleck (Houston, TX) and solubilized in dimethyl sulf-
oxide at 10 mM stock. Dasatinib was purchased from
LC labs (Woburn, MA) and also solubilized in dimethyl
sulfoxide at 10 mM stock. Graphical and statistical data
were generated using either Microsoft Excel or Graph-
Pad Prism.
Cell lines and tissue culture
RCH-ACV (RCH) (DSMZ, Braunschweig, Germany) is a
pediatric BCP-ALL cell line from a patient with recur-
rent disease carrying the E2A-PBX1 t(1;19) chimeric
protein. REH (ATCC, Manassas, VI) is a pediatric ALL
cell line from a patient with recurrent disease carrying
the ETV6-RUNX1 t(12;21) chimeric protein. SUPB15
(ATCC) is a pediatric ALL cell line also from a patient
with recurrent disease carrying the BCR-ABL t(9;22)
translocation. HAL01 cells (DSMZ) are from a pediatric
patient with de novo ALL with the E2A-HLF t(17;19).
K562 (ATCC) is a chronic myeloid leukemia cell line
that also carries the BCR-ABL t(9;22) translocation.
RCH, REH, HAL01, and K562 cells were maintained in
RPMI with 10% FBS, 4 mM glutamine, and 1% penicillin
and streptomycin. SUPB15 cells were maintained in RPMI
with 20% FBS, 4 mM glutamine, 50nM 2-mercaptoethanol,
and 1% penicillin and streptomycin. All cell lines were ori-
ginally obtained from their respective cell banks (DSMZ or
ATCC) and were authenticated by standard RT-PCR for
their respective translocations.
No human subjects were directly involved in the re-
search. Biological samples were obtained with written in-
formed consent. Procurement of biological samples was
approved by the Institutional Review Board of Oregon
Health and Science University (IRB #4422). Patient sam-
ple characteristics are defined as in Additional file 2:
Tables S1 and S2.
Primary ALL xenograft samples were obtained from
the lab of Markus Müschen. Briefly, primary patient
samples were injected into immunodeficient NOD/SCID
mice and expanded. Leukemic cells were then harvested
from the spleen, and mononuclear cells were isolated by
ficoll gradient and used for subsequent drug testing.Drug treatment and viability assay
ALL cell lines (5,000 cells per well) and primary patient
samples (50,000 cells per well) were incubated with in-
creasing concentrations of YM155 (0 to 10 μM) or dasa-
tinib (0 to 10 μM) in RPMI with 10% FBS. After 3 days,
cells were subjected to MTS for assessment of cell via-
bility. All values were normalized to the no drug control
from each respective cell line.siRNA treatment
SUPB15 cells (800,000 cells per treatment) were incubated
with 40 μM siRNA (Dharmacon) of either non-specific
(NS) or ABL1 in siPORTTM siRNA electroporation buffer
(Life Technologies), then electroporated using GenePulser
Xcell (BioRad).
P53 phosphoflow
ALL cells were treated for 24 h with 100 nM YM155 and
fixed with 1% formaldehyde. The cells were then stained
with (Ser 15) phospho-p53 Alexa 488 (Cell Signaling,
Beverly, MA) in PBS/1% BSA. The cells were then sub-
jected to flow cytometry with BD FACS/Aria and inter-
preted by FlowJo (TreeStar, Ashland, OR).
DNA content flow sort
ALL cell lines were grown in RPMI/10% FBS to a con-
centration of 5–10 × 105 cells/ml. The cells were then
washed with PBS/1%FBS and stained with Hoescht
33342 (Life Technologies) at 5 μg/ml or Vibrant DyeCycle
Violet at 5 μM (Molecular Probes) for 30 min at 37°C.
The cells were then sorted by DNA content and then
treated with graduating concentrations of YM155 (0–100
nM YM155) for 24 h. After treatment, the cells were sub-
jected to MTS for assessment of cell viability and Annexin
V staining (Guava Nexin) for activation of apoptosis. ALL
cell lines were also treated with 100 nM YM155 for 24 h,
then washed with PBS and stained with buffer containing
3 mM EDTA, pH 8.0, 0.05% NP-40, 50 μg/ml propidium
iodide, and 1 mg/ml RNAse A in PBS [32].
Expression arrays
P53 RT2 Array (QIAGEN, Germantown, MD) were pur-
chased and used according to the manufacturer’s guide-
lines. ALL cell lines were subjected to 100 nM YM155
for 24 h, and RNA was extracted from the cell line using
RNAeasy (QIAGEN). One microgram of RNA was used
to make first strand cDNA using RT2 First Strand kit.
Quantitative PCR was performed on Opticon 2 (MJ
Research). Generated data was then uploaded to the RT2
Array website.
Phospho proteome assay
Proteome Profiler Arrays (R&D systems, Minneapolis,
MN) were purchased and used according to the manu-
facturer’s guidelines. ALL cell lines were subjected to
100 nM YM155 for 24 h, and 1.2 μg of total protein was
incubated per assay. Results were visualized by chemilu-
minescence using a Lumi-Imager (Boerhinger Mannheim)
with densitometry performed with ImageJ 1.64.
Immunoblot analysis
The cells were washed with phosphate buffered saline
(PBS) and lysed with 1× sodium dodecyl sulfate (SDS)
Chang et al. Journal of Hematology & Oncology  (2015) 8:39 Page 11 of 12loading buffer (75 mM Tris pH 6.8, 3% SDS, 15% glycerol,
8% beta-mercaptoethanol, 0.1% bromophenol blue). All
samples were separated by standard SDS-PAGE and trans-
ferred onto PVDF membrane (Immobilon-FL). Membranes
were blocked with Aquablock tm/EIA/WB (EastCoast Bio)
for 1 h, then incubated with primary antibodies to survivin
(Cell Signaling), (Thr 68) phospho-Chk2 (Cell Signaling),
Chk2 (Cell Signaling), Aurora B kinase (AIM, BD Trans-
duction Labs), MCL1 (Cell Signaling), c-ABL1 (Cell Signal-
ing) and α-tubulin (Cell Signaling) in Aquablock/0.1%
Tween-20 overnight at 4°C. Secondary fluorescent anti-
bodies (Molecular Probes) were used and detected with
Odyssey (LI-COR).
Gamma H2AX staining
Staining was performed as described by Muslimovic
et al. [25]. Briefly, the cells were treated for 24 h with
100 nM YM155 and then partially fixed with 0.2% para-
formaldehyde solution for 5 min and then suspended in
Block 9 buffer. The cells were stained with anti-
H2AXS139PH FITC (Sigma) conjugate to the final con-
centration of 0.6 μg/ml in Block-9 staining buffer for
4 h. Vibrant DyeCycle Violet Stain (Molecular Probes)
was then added for an additional hour, and the cells
were then subjected to flow cytometry with BD FACS/
Aria and data interpreted by FlowJo.
Comet assay
The cells were treated with drug and then processed using
CometAssay®HT (Trevigen). Briefly, after treatment, the
cells were suspended in low melting agarose and plated on
20-well slides. DNA was denatured using alkaline solution
(200 mM sodium hydroxide, 1 mM EDTA) and then
underwent electrophoresis. The cells were then fixed with
70% ethanol, dried, and stained with diluted SYBR® Gold,
and images were captured by epifluorescence microscopy
(Zeiss). Quantitative analysis was performed using Open
Comet (http://www.cometbio.org/) [33].
Additional files
Additional file 1: Figure S1. Dose–response of leukemic samples to
YM155. (A) A selection of primary samples representing sensitive and
resistant samples to YM155. Primary patient samples were treated with
increasing concentrations of YM155 and assayed for viability by MTS.
Viability was then normalized to no drug control. (#) denotes sample
number in the supplemental tables. Black lines represent resistant
samples. Red lines represent sensitive samples. (B) Ph+ BCP-ALL cells
show a dose-dependent decrease in survivin and Mcl1 expression when
treated with YM155. Xenograft samples from Ph+ALL samples 10–668
and10-378 were treated with increasing doses of YM155 (0, 10, 100 nM)
for 24 h and harvested. The cell lines HAL01 (YM155 insensitive) and SUPB15
were also treated as controls. Twenty micrograms of total protein was
loaded per well, separated by gel electrophoresis, transferred and blotted for
survivin, Mcl1, and tubulin. (C) Xenograft samples from Ph+ALL samples
10–378, BLQ5, SFO2, and TXL3 were treated with 1 μM YM155.
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